Recent Updates
Recently added Catalysts
LEXX

Filed by newsfilecorp.com Lexaria Enters Services Contract with TDM Financial KELOWNA, BC--(Marketwired

Key Takeaway: Lexaria Enters Services Contract with TDM Financial KELOWNA, BC--(Marketwired June 8, 2015) - Lexaria Corp. (OTCQB: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") has signed an IR/PR services agreement with TDM Financial valid for the next 60 days. Lexaria expects to receive

Full Press Release Details

Lexaria Enters Services Contract with TDM Financial
KELOWNA, BC--(Marketwired June 8, 2015) - Lexaria Corp.
(OTCQB: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") has signed an IR/PR
services agreement with TDM Financial valid for the next 60 days.
Lexaria expects to receive marketing expertise, video
production services, public relations services, and news distribution to over
700,000 TDM Financial subscribers. Lexaria is paying $18,000 for the services
and no shares nor share purchase options are being awarded. Services are to
Separately, Lexaria has entered a consulting contract designed
to provide services related to joint venture opportunities, sales and
distribution channel efforts, executive search services, strategic financial
advice, and more. The company has issued 250,000 restricted common shares to two
unrelated-party services providers as a result of this agreement.
Lexaria is a food sciences company focused on
the delivery of cannabinoid compounds procured from legal, agricultural hemp,
through gourmet foods based upon its proprietary infusion technologies.
legal CBD oil extracts, grown from agricultural hemp in locations where it is
legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its
patent-pending process to infuse concentrated amounts of CBD within lipids in
its tea, providing more bioactivity and comfort to the body during the
absorption process. Only ViPovaTM has this ground-breaking technology
for CBD/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such
forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the
Company will be able to raise required working capital. Factors which could cause actual results to differ materially
from those estimated by the Company include, but are not limited to, government regulation, managing and
maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements and filings. There is no assurance that the
medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the
Company will experience any growth through participation in these sectors. There is no assurance that existing
capital is sufficient for the Company's needs or that it will need to attempt to raise additional capital. There is no
assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be
successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any
beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion
technology will provide any increase in bioavailability to any individual person. No statement herein has been
evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure
or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.
Last updated: Jun 8, 2015